Not Yet RecruitingNot Applicable

Intermittent-Hypoxia Inhibits Neutrophil Extracellular Traps Formation: Role of Cathelicidins

Taiwan120 participantsStarted 2025-09

Plain-language summary

The study will enroll 80 moderate-to-severe Obstructive sleep apnea (OSA) patients (40 obese) and 40 age-, gender-, and body mass index-matched controls. Venous blood will be collected to isolate neutrophils, which will be tested for the ability to produce neutrophil extracellular traps (NETs) along with the levels of LL-37 and NETs products in the blood. Measurements will be repeat after three months treatment for OSA.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least 20 years old, with moderate to severe OSA (AHI ≥ 15/hour), and willing to participate in the study. Exclusion Criteria: * Under 20 years old, suffering from diseases or conditions that may affect immune function (e.g., tumors, chemotherapy, autoimmune diseases, diabetes, chronic kidney disease, etc.), or unwilling to participate in the study

What they're measuring

NET activity of neutrophils induced by PMA

Timeframe: From enrollment to receiving CPAP therapy for 3 months

DNA-MPO (Myeloperoxidase) complex in plasma

Timeframe: From enrollment to receiving CPAP therapy for 3 months

LL-37 level in plasma

Timeframe: From enrollment to receiving CPAP therapy for 3 months

Trial details

NCT IDNCT07129486

SponsorKun-Ta Chou

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2028-07

Contact for this trial

Kun-Ta Chou, M.D & Ph.D

:(886)-2-2871-2121 hbjoue@vghtpe.gov.tw

View on ClinicalTrials.gov More Obstructive Sleep Apnea (OSA) trials